|
Mar 11
|
IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe
|
|
Mar 10
|
WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
|
|
Feb 27
|
Theratechnologies Inc (THTX) Q4 2024 Earnings Call Highlights: Strong EBITDA Turnaround and ...
|
|
Oct 9
|
Ionis Pharmaceuticals, Inc. (IONS): Among The Stocks With Biggest Upside Potential According to Hedge Funds
|
|
Oct 8
|
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
|
|
Jul 25
|
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?
|
|
Jul 23
|
Ionis (IONS) Up 6% on Detailed Data From Angelman Drug Study
|
|
Jul 23
|
Ionis Pharmaceuticals reports data from Phase I/II trial of Angelman syndrome drug
|
|
Jun 19
|
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
|
|
Jun 18
|
Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema
|
|
Jan 23
|
Ionis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goal
|
|
Jan 22
|
UPDATE 2-Ionis Pharma's genetic disease drug succeeds in late-stage study
|
|
Jan 22
|
Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema
|
|
Jan 22
|
Ionis says rare disease drug succeeds in late-stage HAE study
|
|
Jan 19
|
Insider Sell: EVP CLO & General Counsel Patrick O'Neil Sells 7,744 Shares of Ionis ...
|
|
Dec 30
|
EVP CLO & General Counsel Patrick O'Neil Sells 20,825 Shares of Ionis Pharmaceuticals Inc
|
|
Dec 24
|
Ionis Pharmaceuticals Inc EVP, Chief Scientific Officer C Bennett Sells 22,613 Shares
|
|
Dec 21
|
WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis
|
|
Dec 21
|
CORRECTED-UPDATE 2-US FDA approves Ionis-AstraZeneca's nerve disease drug
|
|
Dec 20
|
12 Most Promising Gene Editing Stocks According to Hedge Funds
|